Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Receivables: 2020-2024

Historic Receivables for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $38.5 million.

  • Maravai Lifesciences Holdings' Receivables fell 21.71% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.4 million, marking a year-over-year decrease of 24.15%. This contributed to the annual value of $38.5 million for FY2024, which is 29.46% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Receivables stood at $38.5 million for FY2024, which was down 29.46% from $54.6 million recorded in FY2023.
  • Maravai Lifesciences Holdings' Receivables' 5-year high stood at $138.6 million during FY2022, with a 5-year trough of $38.5 million in FY2024.
  • Over the past 3 years, Maravai Lifesciences Holdings' median Receivables value was $54.6 million (recorded in 2023), while the average stood at $77.2 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Receivables spiked by 130.33% in 2021 and then slumped by 60.61% in 2023.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Receivables stood at $51.0 million in 2020, then skyrocketed by 130.33% to $117.5 million in 2021, then rose by 17.97% to $138.6 million in 2022, then crashed by 60.61% to $54.6 million in 2023, then dropped by 29.46% to $38.5 million in 2024.